ARO-HIF2 shows promise for advanced kidney cancer

A small phase 1b study of a new medicine called ARO-HIF2 has shown promise for the treatment of people with advanced clear cell renal cell carcinoma (RCC). Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF2. This results […]

read more

Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer

Results from a phase Ib/II study looking at lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) showed that there was a response to treatment and the cancer reduced in size (objective response) in 73% of patients who had not received previous medication for their cancer. There were 143 patients in the […]

read more

Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer

In this phase 1b/2 study the researchers looked at a combination of tivozanib and nivolumab in 25 patients with metastatic renal cell carcinoma (RCC). Tivozanib is a targeted therapy called a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) that blocks the growth of blood vessels to the tumour, while nivolumab is an immune […]

read more

Safety and efficacy of TiNivo in patients with metastatic kidney cancer

Tivozanib is a drug that blocks the blood supply to tumours (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, TKI), and has been shown to be effective and safe in patients with advanced renal cell carcinoma (RCC) when used alone. This study reports the final results from phase 1b/2 clinical trial of tivozanib […]

read more

Safety and efficacy of immunotherapy rechallenge in patients with kidney cancer

There are a number of immune checkpoint inhibitor drugs available for the treatment of people with metastatic renal cell carcinoma (RCC), but the efficacy and safety of treating patients with two separate lines of immunotherapy (rechallenge) is unknown. This study looked at the safety and efficacy of rechallenge with an immune checkpoint inhibitor in patients […]

read more

Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer

A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]

read more

Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more

ASCO 2019: Safety and efficacy of immune checkpoint inhibitors in patients with pre-existing autoimmune disorders

This study was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago last month. The trial looked at 103 patients with a variety of different autoimmune disorders, such as psoriasis (22%), thyroiditis (20%), rheumatoid arthritis (13%), polymyalgia rheumatica (8%), inflammatory bowel disease (6%), multiple sclerosis (3%) and lupus (3%) who […]

read more

Real-world outcomes of nivolumab and cabozantinib for metastatic kidney cancer

A retrospective study using data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) dataset looked at the efficacy of nivolumab (225 patients) and cabozantinib (53 patients) when used to treat metastatic renal cell carcinoma (RCC) in the real world. The study found similar outcomes for patients treated with nivolumab and cabozantinib in the […]

read more
Showing 1 to 10 of 14 results
  TOP